Cytolytic T lymphocytes are activated as a result of T cell receptor recognition of foreign peptide complexed to class I MHC proteins. It is clear, however, that effective activation of the CTL also involves interactions of 'accessory' proteins on the CTL (including CD8, LFA-1 and VLA's) with ligands on the antigen-bearing cell. Using artificial membranes having well defined and easily varied ligand compositions, considerable progress has been made in defining the qualitative and quantitative contributions that these interactions can make to activation of immediate responses (eg. degranulation) by cloned effector CTL. Proposed studies will extend this approach to systematically assess the relative roles of the accessory interactions and lymphokines in activating CD8+ precursor CTL for proliferation and differentiation to effector CTL. In addition, the requirements for activating naive versus primed (in vivo) precursor CTL clearly differ, and studies will be done to determine if this results from differences in ligand interaction requirements, cytokine requirements, or both. Both allogeneic and self-restricted, peptide specific CTL responses will be studied. Antigen-bearing artificial membranes have been found to significantly affect in vivo generation of CTL responses. Administration of antigen in this form does not result in a detectable CTL response, but administration to mice along with live, antigen-bearing cells results in a dramatic augmentation of the response compared to that obtained in mice receiving only stimulator cells. Augmentation does not simply result from increased antigen load; the effect is unique to antigen on cell-size artificial membranes and appears to occur at the level of precursor CTL activation. The ability to significantly augment CTL response levels has implications for tumor and virus disease therapy, and experiments examining cytolytic responses to syngeneic tumors, and effects on tumor growth and host survival, have demonstrated the potential of this approach. In the proposed project, the requirements for in vivo stimulation/augmentation will be studied in parallel with the in vitro activation studies described above. Studies are also proposed to determine the mechanism(s) by which antigen-bearing artificial membranes are able to uniquely modulate in vivo response levels. It is anticipated that these experiments will provide insight into the parameters which influence the in vivo generation of CTL responses, and suggest approaches for prevention and therapy of diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI034824-05
Application #
2442571
Study Section
Experimental Immunology Study Section (EI)
Project Start
1993-07-01
Project End
1998-06-30
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pathology
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Gerner, Michael Y; Heltemes-Harris, Lynn M; Fife, Brian T et al. (2013) Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 191:1011-5
Curtsinger, Julie M; Agarwal, Pujya; Lins, Debra C et al. (2012) Autocrine IFN-ýý promotes naive CD8 T cell differentiation and synergizes with IFN-ýý to stimulate strong function. J Immunol 189:659-68
Curtsinger, Julie M; Mescher, Matthew F (2010) Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 22:333-40
Gerner, Michael Y; Mescher, Matthew F (2009) Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol 182:2726-37
Agarwal, Pujya; Raghavan, Arvind; Nandiwada, Sarada L et al. (2009) Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol 183:1695-704
Xiao, Zhengguo; Casey, Kerry A; Jameson, Stephen C et al. (2009) Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol 182:2786-94
Hammerbeck, Christopher D; Mescher, Matthew F (2008) Antigen controls IL-7R alpha expression levels on CD8 T cells during full activation or tolerance induction. J Immunol 180:2107-16
Gerner, Michael Y; Casey, Kerry A; Mescher, Matthew F (2008) Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol 181:155-64
Mescher, Matthew F; Agarwal, Pujya; Casey, Kerry A et al. (2007) Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation. Semin Immunol 19:153-61
Xiao, Zhengguo; Mescher, Matthew F; Jameson, Stephen C (2007) Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J Exp Med 204:2667-77

Showing the most recent 10 out of 36 publications